目的 探究银丹心脑通软胶囊联合缬沙坦治疗原发性高血压的临床疗效。方法 选取2015年10月—2016年10月河南省信阳市第三人民医院心血管内科收治的原发性高血压患者201例，随机分为对照组（100例）和治疗组（101例）。对照组患者口服缬沙坦胶囊，1粒/次，1次/d。治疗组在对照组的治疗基础上口服银丹心脑通软胶囊，2粒/次，3次/d。所有患者均连续治疗8周。观察两组的临床疗效，比较两组治疗前后收缩压、舒张压、血压变异性、血糖异常、血脂异常的变化情况。结果 治疗后，对照组和治疗组的总有效率分别为86.0%、97.0%，两组比较差异有统计学意义（P< 0.05）。治疗后，两组患者收缩压、舒张压、收缩压和舒张压的血压变异性均较治疗前明显降低，同组治疗前后差异有统计学意义（P< 0.05）；治疗后，治疗组收缩压、舒张压、收缩压和舒张压的血压变异性均显著低于对照组，两组比较差异有统计学意义（P< 0.05）。治疗后，两组患者血糖异常、血脂异常的例数和异常率均较治疗前显著降低，同组治疗前后差异有统计学意义（P< 0.05）；治疗后，治疗组血糖异常、血脂异常的例数和异常率均低于对照组，两组比较差异有统计学意义（P< 0.05）。对照组和治疗组的不良反应发生率分别为23.0%、6.9%，两组比较差异有统计学意义（P< 0.05）。结论 银丹心脑通软胶囊联合缬沙坦治疗原发性高血压具有显著的临床疗效，可降低患者血压、血压变异性，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Yindan Xinnaotong Capsules combined with valsartan in treatment of primary hypertension. Methods Patients (201 cases) with primary hypertension in Department of Cardiovascular Medicine of Xinyang Third People's Hospital in Henan from October 2015 to October 2016 were randomly divided into control (100 cases) and treatment (101 cases) groups. Patients in the control group were po administered with Valsartan Capsules, 1 grain/time, once daily. Patients in the treatment group were po administered with Yindan Xinnaotong Capsules, 2 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the changes of systolic blood pressure, diastolic blood pressure, blood pressure variability, abnormal blood glucose, dyslipidemia in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 86.0% and 97.0%, respectively, and there was difference between two groups (P < 0.05). After treatment, systolic blood pressure, diastolic blood pressure, and blood pressure variability in two groups decreased statistically, and the difference was statistically significant in the same group (P < 0.05). After treatment, systolic blood pressure, diastolic blood pressure, and blood pressure variability in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the number of cases and the abnormal rate of abnormal blood glucose and dyslipidemia in two groups decreased statistically, and the difference was statistically significant in the same group (P < 0.05). After treatment, the number of cases and the abnormal rate of abnormal blood glucose and dyslipidemia in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the incidence of adverse reactions in the control and treatment groups were 23.0% and 6.9%, respectively, and there was difference between two groups (P < 0.05). Conclusion Yindan Xinnaotong Capsules combined with valsartan has a significant effect in treatment of primary hypertension, and can reduce the blood pressure and blood pressure variability, which has a certain clinical application value.